270 related articles for article (PubMed ID: 28676030)
1. Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option.
Bramblett T; Teleb M; Albaghdadi A; Agrawal H; Mukherjee D
Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):80-85. PubMed ID: 28676030
[TBL] [Abstract][Full Text] [Related]
2. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
3. Entresto, a New Panacea for Heart Failure?
Khalil P; Kabbach G; Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2018; 16(1):5-11. PubMed ID: 29532764
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Gori M; Volterrani M; Piepoli M; Senni M
Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
[TBL] [Abstract][Full Text] [Related]
6. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
Gori M; Senni M
Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078
[TBL] [Abstract][Full Text] [Related]
8. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
[TBL] [Abstract][Full Text] [Related]
9. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
10. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
11. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Voors AA; Gori M; Liu LC; Claggett B; Zile MR; Pieske B; McMurray JJ; Packer M; Shi V; Lefkowitz MP; Solomon SD;
Eur J Heart Fail; 2015 May; 17(5):510-7. PubMed ID: 25657064
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
13. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
Andersen MB; Simonsen U; Wehland M; Pietsch J; Grimm D
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):14-22. PubMed ID: 26280447
[TBL] [Abstract][Full Text] [Related]
14. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
Pham AQ; Patel Y; Gallagher B
J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789
[TBL] [Abstract][Full Text] [Related]
15. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
McMurray J; Packer M; Desai A; Gong J; Greenlaw N; Lefkowitz M; Rizkala A; Shi V; Rouleau J; Solomon S; Swedberg K; Zile MR; Andersen K; Arango JL; Arnold M; Bĕlohlávek J; Böhm M; Boytsov S; Burgess L; Cabrera W; Chen CH; Erglis A; Fu M; Gomez E; Gonzalez A; Hagege AA; Katova T; Kiatchoosakun S; Kim KS; Bayram E; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires F; Refsgaard J; Senni M; Sibulo AS; Silva-Cardoso J; Squire I; Starling RC; Vinereanu D; Teerlink JR; Wong R;
Eur Heart J; 2015 Feb; 36(7):434-9. PubMed ID: 25416329
[TBL] [Abstract][Full Text] [Related]
16. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
18. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
19. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Macdonald PS
Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
[TBL] [Abstract][Full Text] [Related]
20. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Nguyen E; Weeda ER; White CM
J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
